

Deutsches Patent- und Markenamt

Deutsch s Patent- und Markenamt · 80297 München

Patentanwälte
Strehl, Schübel-Hopf & Partner
Maximilianstr. 54

80538 München

München, den 23. April 2003

Telefon: (0 89) 21 95 - 4220

Aktenzeichen: 102 33 412.9-44
Ihr Zeichen: DEA-53954
Anmelder nr.: 12189820
4SC AG

Erhalten
02 MAI 2003
Strehl et al.

Bitte Aktenzeichen und Anmelder bei
allen Eingaben und Zahlungen angeben

Zutreffendes ist angekreuzt und/oder ausgefüllt

Prüfungsantrag, Einzahlungstag am 22. Oktober 2002

Eingabe vom eingegangen am

Die weitere Prüfung der oben genannten Patentanmeldung hat zu dem nachstehenden Ergebnis geführt.

Zur Äußerung wird eine Frist von

12 Monat(en)

gewährt, die mit der Zustellung beginnt.

Für Unterlagen, die der Äußerung gegebenenfalls beigefügt werden (z.B. Beschreibung, Beschreibungsteile, Patentansprüche, Zeichnungen), sind je **zwei** Ausfertigungen auf gesonderten Blättern erforderlich. Die Äußerung selbst wird nur in einfacher Ausfertigung benötigt.

Werden die Beschreibung, die Patentansprüche oder die Zeichnungen im Laufe des Verfahrens geändert, so hat der Anmelder, sofern die Änderungen nicht vom Deutschen Patent- und Markenamt vorgeschlagen sind, im Einzelnen anzugeben, an welcher Stelle die in den neuen Unterlagen beschriebenen Erfindungsmerkmale in den ursprünglichen Unterlagen offenbart sind.

In diesem Bescheid ist folgende Entgegenhaltung erstmalig genannt (bei deren Nummerierung gilt diese auch für das weitere Verfahren):

(1) EP 200 377 B1

2. 5. 04 05
2. 1. 04 05

Hinweis auf die Möglichkeit der Gebrauchsmusterabzweigung

Der Anmelder einer mit Wirkung für die Bundesrepublik Deutschland eingereichten Patentanmeldung kann eine Gebrauchsmusteranmeldung, die den gleichen Gegenstand betrifft, einreichen und gleichzeitig den Anmeldetag der früheren Patentanmeldung in Anspruch nehmen. Diese Abzweigung (§ 5 Gebrauchsmustergesetz) ist bis zum Ablauf von 2 Monaten nach dem Ende des Monats möglich, in dem die Patentanmeldung durch rechtskräftige Zurückweisung, freiwillige Rücknahme oder Rücknahmefiktion erledigt, in Einspruchsverfahren abgeschlossen oder - im Falle der Erteilung des Patents - die Frist für die Beschwerde gegen den Erteilungsbeschluss fruchtlos verstrichen ist. Ausführliche Informationen über die Erfordernisse einer Gebrauchsmusteranmeldung, einschließlich der Abzweigung, enthält das Merkblatt für Gebrauchsmusteranmelder (G 6181), welches kostenlos beim Deutschen Patent- und Markenamt und den Patentinformationszentren erhältlich ist.

Annahmestelle und
Nachtbriefkasten
nur
Zweibrückenstraße 12

Hauptgebäude
Zweibrückenstraße 12
Zweibrückenstraße 5-7 (Breiterhof)
Markenabteilungen:
Cincinnatistraße 64
81534 München

Hausadresse (für Fracht)
Deutsches Patent- und Markenamt
Zweibrückenstraße 12
80331 München

Telefon (0 89) 2195-0
Telefax (0 89) 2195-2221
Internet: <http://www.dpma.de>

Bank:
BBk München
Kto.Nr.:700 010 54
BLZ:700 000 00

P 2401.1 S-Bahnanschluss im
08.00 Münchner Verkehrs- und
05/01 Tarifverbund (MVV): ➔

Zweibrückenstr. 12 (Hauptgebäude)
Zweibrückenstr. 5-7 (Breiterhof)
S1 - S8 Haltestelle Isartor

Cincinnatistraße:
S2 Haltestelle Fasangarten
Bus 98 / 99 (ab S-Bahnhof Giesing) Haltestelle Cincinnatistraße

Der Prüfung werden die am 17. September 2002 eingegangenen Unterlagen zugrunde gelegt.

Die Verbindungen der allgemeinen Formel I sind nicht mehr neu.

In (1), Anspruch 1 wird ebenfalls eine allgemeine Formel aufgezeigt, die Verbindungen nach geltendem Anspruch 1 umfasst. So kommt man mit den Bedeutungen aus (1), Anspruch 1 $R^1 = \text{Wasserstoff}$, $R^2 = \text{Wasserstoff}$, $R^3 = \text{Cycloalkyl}$ und $m = 1 - 5$ zwanglos zu den anmeldungsgemäßen Verbindungen.


Die vorgeschlagene Verwendung der beanspruchten Verbindungen unterscheidet sich von der in (1) aufgezeigten.

Die Verwendungsansprüche sind bis jetzt aber rein aufgabenhaft formuliert. Auch in den Beispielen sind bis jetzt lediglich Testmöglichkeiten aufgezeigt worden. Messergebnisse selbst sind nicht offenbart.

Deshalb lässt sich die Erfindungshöhe der vorgeschlagenen Verwendung nicht beurteilen.

Aus den genannten Gründen ist mit der Zurückweisung der vorliegenden Anmeldung mangels Neuheit zu rechnen.

Prüfungsstelle für Klasse C 07 C


Dr. Fricke

Anlagen

Abl. v. 1 Entgegenh.

Rie.

⑯



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑮ Publication number:

0 200 377 B1

⑯

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of patent specification: 09.10.91 ⑮ Int. Cl.⁵: C07C 259/04, A61K 31/16
⑯ Application number: 86302449.3
⑯ Date of filing: 02.04.86

⑯ Hydroxamates.

⑯ Priority: 04.04.85 US 720102

⑯ Date of publication of application:
10.12.86 Bulletin 86/45

⑯ Publication of the grant of the patent:
09.10.91 Bulletin 91/41

⑯ Designated Contracting States:
BE CH DE FR GB IT LI LU NL SE

⑯ References cited:
US-A- 3 282 986
US-A- 4 122 186

CHEMICAL ABSTRACTS, vol. 88, no. 13, 27th
March 1978, page 505, abstract no. 89505f,
Columbus, Ohio, US; Y. ENDO et al.:
"Reaction of arylhydroxamic acids with ben-
zene"

JOURNAL OF THE CHEMICAL SOCIETY, sec-
tion B, part 1, 1971, pages 677-681, The
Chemical Society, London, GB; T.R. OLIVER
et al.: "The mechanism of oxidation of
hydroxamic acids by alkaline ferricyanide"

The Chemistry of Acid Derivatives, supple-
ment B, par 2, page 1007 (1979). John Wiley

and Sons, Chichester, New York

⑯ Proprietor: E.R. Squibb & Sons, Inc.
Lawrenceville-Princeton Road
Princeton, N.J. 08540-4000(US)

⑯ Inventor: Haslanger, Martin Frederick
53 West Glen Avenue
Ridgewood New Jersey(US)
Inventor: Karanewsky, Donald Steven
8 Charred Oak Lane
East Windsor New Jersey(US)

⑯ Representative: Thomas, Roger Tamlyn et al
D. Young & Co. 10 Staple Inn
London WC1V 7RD(GB)

EP 0 200 377 B1


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to the use of hydroxamates as inhibitors of Δ^5 -lipoxygenase and thus as antiallergy agents. These compounds have the structural formula

5


10



15

wherein R^1 is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl or

15



20

wherein n is 1 to 4 and X is hydroxy, lower alkoxy, amino $\text{C}_1\text{-C}_4$ -alkylamino or $\text{C}_1\text{-C}_4$ -dialkylamino; R^2 is hydrogen or lower alkyl; and

25


R^3 is $\text{C}_1\text{-C}_{20}$ alkyl, $\text{C}_3\text{-C}_{20}$ alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, alkoxy, lower alkenyloxy, aryl-alkoxy or cycloalkyloxy; and m is 0 to 5.

25

Such compounds where R^2 is lower alkyl are novel compounds. Also novel are N-hydroxy-N-methyl-[1,1'-biphenyl]-4-acetamide, N(1,1'-dimethylethyl)-N-hydroxy-[1,1'-biphenyl]-4-acetamide, N-hydroxy-N-phenylbenzenebutanamide, N-hydroxy-N-(phenylmethyl)cyclohexane acetamide, N-hydroxy-N-(phenylmethyl)benzenebutanamide and N-hydroxy-N-pentylbenzenebutanamide.

Where R^1 is


30



35

and R^2 is H, the above compounds may form binary or dibasic salts such as with alkali metal, such as a dilithium, disodium or dipotassium salt; where R^1 is other than

35



40

and R^2 is H, the above compounds will form only a monobasic salt. In addition, the compounds of formula I will form salts with dicyclohexylamine or other amines as well as with tris(hydroxymethyl)aminomethane, glucamine and other amines.

45

The term "lower alkyl" or "alkyl" as employed herein by itself or as part of another group includes both straight and branched chain radicals of up to 12 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including a halo-substituent, such as F, Br, Cl or I or CF_3 , an alkoxy substituent, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloalkyl substituent, an alkylcycloalkyl substituent, hydroxy, an alkylamino substituent, an alkanoylamino substituent, an arylcarboxylamino substituent, a nitro substituent, a cyano substituent, a thiol substituent or an alkylthio substituent.

50

The term " $\text{C}_1\text{-C}_{20}$ alkyl" as employed herein includes the above alkyl radicals of 1 to 8 carbons and more as well as alkyl radicals of up to and including 20 carbon atoms, preferably from 4 to 16 carbons, such as in addition to the C_1 to C_{12} alkyl radicals set out above, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosanyl including all isomers thereof with or without the above substituents.

The term "cycloalkyl" employed herein by itself or as part of another group includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl,

cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups, an aryl group, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarboxylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and 1 or 2 alkylthio groups.

The term "aryl" or "Ar" as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl, substituted phenyl or substituted naphthyl wherein the substituent on either the phenyl or naphthyl may be 1 or 2 lower alkyl groups, 1 or 2 halogens (Cl, Br, or F), 1 or 2 lower alkoxy groups, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, 1 or 2 thiol groups and/or 1 or 2 alkylthio groups.

The term "aralkyl", "aryl-alkyl" or "aryl-lower alkyl" as used herein refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.

15 The term "lower alkanyl" or "alkenyl" as employed herein by itself or as part of another group includes an unsaturated hydrocarbon group having from 3 to 8 carbons and a single carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-but enyl, 2-but enyl, 3-but enyl and the like.

The term "C₃-C₂₀ alkenyl" includes straight or branched chain radicals of from 3 to 20 carbons, preferably 4 to 16 carbons in the normal chain, which include one double bond in the normal chain, such as any of the lower alkenyl groups mentioned above as well as 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 2-tridecenyl, 3-tetradecenyl, 1-pentadecenyl, 2-hexadecenyl, 4-heptadecenyl, 7-octadecenyl, 6-nonadecenyl and 8-eicosenyl, 2,5-hexadienyl, 3,7-octadienyl, 2,6-decadienyl, 3,9-pentadecadienyl, 4,12-nonadecadienyl, including all isomers thereof and the like.


The term "aryl-alkenyl" as used herein refers to lower alkenyl groups as discussed above having an aryl substituent.

The term "lower alkoxy", "alkoxy", "lower alkenyloxy", "cycloalkoxy" or "aralkoxy" includes any of the above lower alkyl, alkyl, lower alkenyl, cycloalkyl or aralkyl groups linked to an oxygen atom.

The term "alkanoyl" as used herein by itself or as part of another group refers to a lower alkyl group linked to a carbonyl group.

30 The term "halogen" or "halo" as used herein refers to chlorine, bromine, fluorine or iodine with chlorine being preferred.

The terms " $(CH_2)_m$ " and " $(CH_2)_n$ ", include a straight or branched chain radical having from 0 to 5 carbons in the normal chain in the case of " $(CH_2)_m$ ", and 1 to 4 carbons in the normal chain in the case of " $(CH_2)_n$ " and may contain one or more lower alkyl or halo substituents. Examples of $(CH_2)_m$ and $(CH_2)_n$ groups include CH_2 ,




Preferred are those compounds of the invention wherein m is 1, 2 or 3, R^1 is alkyl, such as m thyl, pentyl, phenyl or phenylalkyl, R^2 is H and R^3 is biphenyl, cycloalkyl or phenyl.

55 The various compounds of the invention may be prepared as described below.

Compounds of formula I wherein R² is H may be prepared as follows.

Compounds of formula I WI




5

is subjected to a coupling reaction by reacting A with an O-protected hydroxyl amine of the structure B

B $\text{NH}_2 - \text{O} - \text{Protecting group}$

10 (wherein the protecting group is benzyl, tetrahydropyranyl, methylthiomethyl or methoxymethyl) at a temperature within the range of about -15 to about 25 °C, employing a molar ratio of B:A within the range of about 1:1 to about 2.5:1, in the presence of an activating catalyst such as 1-hydroxybenzotriazole and a coupling reagent such as N,N'-dicyclohexylcarbodiimide (DCC) and an organic base such as triethylamine to form hydroxamate II

15




20

The hydroxamate II is then reacted with halide C

C $\text{Hal}-\text{R}^{1a}$

25 (wherein Hal is I, Br or Cl and R^{1a} is the same as R^1 where R^1 is to be lower alkyl, aryl, cycloalkyl, aralkyl or


30



wherein X is lower alkoxy in the final product)

at a temperature within the range of about 50 to about 110 °C, employing a molar ratio of C:II of within the range of about 1:1 to about 3:1, in the presence of a base such as sodium hydride and an inert organic solvent such as toluene or benzene to form compound III


40



45


The protected compound III where the protecting group is benzyl is then subjected to hydrogenolysis and hydrogenation by treating compound III with hydrogen in the presence of a palladium hydroxide on carbon catalyst to form the compounds of the invention IV

50




wherein R^1 is $(\text{CH}_2)_n - \text{CO}_2\text{alkyl}$, alkyl, aryl, cycloalkyl or aralkyl, R^2 is H and R^3 is $\text{C}_1\text{-C}_{20}$ alkyl or aryl-alkyl. However, where R^1 is to be

55



5 the ester group in IV may be removed by treating with an alkali metal hydroxide such as lithium hydroxide in an organic solvent such as dioxane or methanol.
Where R^1 in the final product is to be


10



15 that is, n is 1, and X is OH or alkoxy, then the protected compound II will be reacted with allyl bromide ($\text{BrCH}_2\text{CH}=\text{CH}_2$) to form the intermediate IIIa

IIIa

20




25

which is then treated with ozone, Jones reagent ($\text{H}_2\text{CrO}_4/\text{H}_2\text{SO}_4/\text{H}_2\text{O}$) and diazomethane to form the ester IIIb

30

IIIb




35

Ester IIIb may then be subjected to hydrogenolysis as described above to form the ester IVa of the invention

40


IVa



45

which may then be hydrolyzed to the corresponding acid IVb.

50




55 Where it is desired to form compounds wherein R^3 $\text{C}_3\text{-C}_{20}$ is alkenyl or aryl-alkenyl and/or R^1 is lower alkenyl, the protecting group (where the protecting group is either tetrahydropyanyl or methoxymethyl) may be removed by treating III or IIIb with acetic acid without reducing the double bond in the R^3 group and/or in the R^1 group. Alternatively, where the protecting group is methylthiomethyl, it can be removed by

treatment with CuO-CuCl₂ in aqueous acetone without reducing the double bond in the R³ group or in the R¹ group.


Where it is desired to prepare compounds of the invention wherein R¹ is

5



and X is amino, alkylamino or dialkylamino (wherein each alkyl of the dialkyl group is the same or different),
10 then compound III wherein R¹ is


15



is hydrolyzed to the corresponding acid IIIA by reacting III with lithium hydroxide in the presence of a solvent such as dioxane as described above

20


IIIA



25

The acid IIIA is then treated with an activating agent such as isobutylchloroformate, organic base such as triethylamine and inert organic solvent such as acetonitrile and reacted with ammonium hydroxide where X is amino or with an appropriate alkylamine or dialkylamine where X is alkylamino or dialkylamino, respectively, to form amide IIIB

IIIB




35

40 Compound IIIB where the protecting group is benzyl may then be subjected to hydrogenolysis and hydrogenation as described above to form IVA

IVA

45



50


Compound IIIB where the protecting group is tetrahydropyranyl may also be treated with acetic acid to remove the protecting group to form the corresponding compound wherein R³ is alkenyl.

Compounds of the invention wherein R¹ is hydrogen may be prepared by removing the protecting group of compound II, for example, by treating II, where the protecting group is tetrahydropyranyl, with an acid catalyst such as pyridinium p-toluenesulfonate in the presence of an alcoholic solvent such as methanol, to form IIA

55

IIA

5

(wherein R^2 is hydrogen)

Compound IIA may be reduced as described above to form the corresponding compound wherein R^3 is C_3 to C_{20} alkyl.

Preparation of compounds of formula IIA wherein R^2 is alkyl, that is compound V, is described hereinafter.


Compounds of the invention wherein R^2 is alkyl and R^3 is C_1 - C_{20} alkyl or aryl-alkyl may be prepared by subjecting acid A to a coupling reacting as described above except that the hydroxylamine coupling reagent employed has the structure

D $\text{NH}_2\text{-O-alkyl}$

to form the hydroxamate V

20

V




25

The hydroxamate V is then reacted with halide C as described above to form the compound of the invention of the structure VI

30


VI



35

Compound VI may be reduced as described above to form the corresponding compound wherein R^3 is C_3 - C_{20} alkyl and/or may be hydrolyzed (where R^1 is

40




to form the corresponding acid.

45 Compounds of formula I wherein R^2 is H may also be prepared by treating the acid A


50

A



55

with oxalyl chloride in the presence of an inert organic solvent such as benzene, ethyl ether or tetrahydrofuran under an inert atmosphere such as argon to form the corresponding acid chloride E




which is then reacted with hydroxylamine F



15 in the presence of an inert organic solvent such as tetrahydrofuran and in an organic base such as triethylamine to form the compounds of the invention IIA




25 Compounds of formula I wherein R^2 is alkyl may be prepared from compound IIA by treating IIA with a base such as sodium hydride and an alkyl halide (Hal-Alkyl) in the presence of an inert organic solvent such as tetrahydrofuran and dimethylformamide, to form compounds of the invention VIA



35 In an alternative method, compounds of formula I of the invention may be prepared by subjecting acid A to a coupling reaction by reacting acid A with an amine salt of the structure IX




45 wherein the protecting group is $C_6H_5CH_2$, CH_3SCH_2 , or tetrahydropyranyl and the like and M is an alkali metal such as Li, Na or K, or M is tetrabutylammonium, dissolved in an inert organic solvent such as dioxane, acetone, dimethylformamide or acetonitrile, in the presence of an activating agent such as isobutylchloroformate, an organic base such as triethylamine, and an inert organic solvent such as acetone, dioxane, dimethylformamide or acetonitrile. The coupling reaction is carried out at temperatures within the range of about -15 to about 25 °C, employing a molar ratio of IX:A within the range of about 1:1 to about 3:1, to form the intermediate acid of the structure X



55 The acid X is then esterified, for example, by reacting X with a diazoalkane, such as diazomethane in ether, to form the ester XI

XI




5

The ester XI is then subjected to a deprotecting procedure wherein XI is treated with cupric oxide and cupric chloride in an aqueous organic solvent mixture such as aqueous acetone (in the case where the protecting group is CH_3SCH_2) or XI is treated with H_2 in the presence of a palladium hydroxide on carbon catalyst in the case where the protecting group is $\text{C}_6\text{H}_5\text{CH}_2$; the deprotected compound is then immediately hydrolyzed by treatment with lithium hydroxide or other base in the presence of an inert organic solvent such as dioxane, methanol or acetonitrile to form the acid compound of the invention of the structure XII

15

XII




20

The amine salt IX may be prepared from the hydroxylamine of the structure G

G Protecting group - ONH_2

25 by reacting G with acid halide H

H



30

in the presence of 2,6-lutidine and methylene choride to form the compound J

35


J



Compound J is then cyclized by reacting same with a base such as sodium hydride, in the presence of 40 benzene to form the protected N-hydroxy lactam K

45

K




50

For the preparation of the lactam where the protecting group is CH_3SCH_2 , the lactam K, where the protecting group is benzyl, can be deprotected by a hydrogenolysis reaction wherein K is treated with hydrogen in the presence of a palladium hydroxide on carbon catalyst and an inert organic solvent such as ethanol, methanol or ethyl acetate to form the hydroxy lactam XIII

55

XIII


5

10 Lactam XIII can be treated with a protecting compound LL Hal-CH₂SCH₃

15 In the presence of weak base such as potassium carbonate or triethylamine and an inert organic solvent such as dimethyl formamide to form the protected compound XIV

XIV

20



25

Either K or XIV is next hydrolyzed by treatment with base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in the presence of dioxane to form the starting amine salt IX.

The starting acid compounds A are commercially available compounds.

30 The compounds of the invention are delta-5-lipoxygenase inhibitors and prevent leukotriene C₄ formation in macrophages (Samuelsson, B., Science, Vol. 220, p. 568-575, 1983). The administration of compounds of this invention to humans or animals provides a method for treating allergy of a reagin or non-reagin nature. Asthma is preferably treated but any allergy wherein leukotrienes are thought to be involved as pharmacological mediators of anaphylaxis can be treated. For example, the compounds of this invention can be used for treatment of such conditions as allergic rhinitis, food allergy and urticaria as well as asthma.

35

An effective but essentially non-toxic quantity of the compound is employed in treatment.

The compounds of the invention can be administered orally or parenterally to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs, and the like in an effective amount within the dosage range of about 1 to 100 mg/kg, preferably about 1 to 50 mg/kg and especially about 2 to 25 mg/kg on a regimen in single or 2 to 4 divided daily doses.

40

The active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formula I. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc. as called for by accepted pharmaceutical practice. Also as indicated in the discussion above, certain members additionally serve as intermediates for other 45 members of the group.

The following Examples represent preferred embodiments of the invention. Unless otherwise indicated, all temperatures are expressed in °C. TLC plates were visualized by spraying and heating with 5% phosphomolybdic acid in ethanol. HP-20 refers to a high porous divinylbenzene-polystyrene polymer resin.

50 Example 1

N-Hydroxy-N-methyl[1,1'-biphenyl]-4-acetamideTo a stirring solution of 1,1'-biphenylmethyl carboxylic acid (1.0 g, 4.7 mmol) in 10 ml of dry benzene, under argon, was added oxalyl chloride (0.41 ml, 2.0 eq.). To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product was diluted with 5 ml of tetrahydrofuran and added dropwise to a 0 °C solution of N-methylhydroxylamine hydrochloride (785 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (1.93 ml, 3.0 eq.). The solution

was stirred for 0.5 hour at 0 °C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave an off-white solid which was recrystallized from hot hexane/EtOAc, to give title product (836 mg, 74%) as a yellow solid.

5 TLC (1:1) Hexane:EtOAc R_f=0.11, (UV + PMA, visualization). Product streaks to baseline.
 Anal Calcd for C₁₅H₁₅NO₂: C, 74.67; H, 6.27; N, 5.81
 Found: C, 74.62; H, 6.28; N, 5.68 M.P. 132-134 °C.

Example 2

10 N-(1,1-Dimethylethyl)-N-hydroxy[1,1'-biphenylyl]-4-acetamide

To a stirring solution of 1,1'-biphenyl-methylcarboxylic acid (500 mg, 2.36 mmol) in 10 ml of dry benzene under argon, was added oxalyl chloride (0.23 ml, 2.0 eq.). To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour, then reduced on the rotovap without heating. The crude product, a white solid, was dissolved in 5 ml tetrahydrofuran and added dropwise to a 0 °C solution of N-t-butylhydroxylamine hydrochloride (593 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (1.0 ml, 3.0 eq.). The solution was stirred for 1 hour at 0 °C, then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave an oil, which upon standing a crystal formed. This solid was recrystallized from hot hexane/EtOAc, to give title product, 69 mg (10%), as long light yellow needles.
 TLC (1:1) Hexane:EtOAc R_f0.40, UV + CeMo. Product streaks to baseline.
 Anal Calcd for C₁₈H₂₁NO₄: C, 76.30; H, 7.47; N, 4.94
 Found: C, 76.43; H, 7.63; N, 4.81 M.P. 133-135 °C.

Example 3

N-Hydroxy-N-phenylbenzenebutanamide

30 To a stirring solution of 3-phenylpropylcarboxylic acid (500 mg, 3.1 mmol) in 10 ml of dry benzene under argon was added oxalyl chloride (0.30 ml, 1.1 eq.). To this solution was added dimethylformamide dropwise in 10 minute intervals, until no gas was evolved and the solution turned slightly cloudy (2 drops). The mixture was stirred for 1 hour then reduced on the rotovap without heating. The crude product was diluted with 5 ml of tetrahydropyran and added dropwise to a 0 °C solution of N-phenylhydroxylamine (666 mg, 2 eq.) in 20 ml of THF:H₂O (1:1) with triethylamine (0.85 ml, 2.0 eq.). The solution was stirred for 1 hour at 0 °C then allowed to warm to room temperature and stir overnight. The reaction mixture was diluted with EtOAc and the organic layer was washed with H₂O, 1N HCl (2X), and brine, then dried over anhydrous MgSO₄. Concentration in vacuo gave a white solid which was recrystallized from hot hexane/EtOAc, to give title product (451 mg, 58%) as a flat golden crystalline solid.
 40 TLC (1:1) Hexane:EtOAc R_f=0.47, UV + CeMo
 Anal Calcd for C₁₆H₁₇NO₂: C, 75.27; H, 6.71; N, 5.49
 Found: C, 75.55; H, 6.71; N, 5.30
 M.P. 90-91.5 °C.

45 **Example 4**

N-Hydroxy-N-(phenylmethyl)cyclohexaneacetamide

A. O-Tetrahydropyran-2-ylhydroxylamine (H₂N-OTHP)

50 With gentle heating N-hydroxyphthalimide (10.0 g, 61.4 mM) was dissolved in dry CH₂Cl₂ (70 ml) and dioxane (80 ml), then dihydropyran (6.16 ml, 67.6 mM, 1.1 eq) and p-toluenesulfonic acid monohydrate (200 mg, 2% by weight) were added and the mixture stirred for 2 hours at room temperature under argon. The mixture was then washed successively with saturated NaHCO₃ (2X) and brine, dried over anhydrous Na₂SO₄ and evaporated to a white solid. The solid was triturated with hexane and filtered to give 13.43 g (89%) of O-tetrahydropyranyl hydroxyphthalimide as a white solid m.p. 123-125 °C with consistent NMR (60 MHz, CDCl₃) spectral data. TLC (1:1) EtOAc-Hex, R_f=0.75, UV + PMA.

To a stirred solution of the O-THP hydroxyphthalimide (13.0 g, 52.6 mM) in dry benzene (30 ml) was added methyl hydrazine (2.82 ml, 53.0 mM) and the mixture heated at 80 °C for 15 minutes under argon.

The mixture was concentrated to a 50 ml volume then vacuum distilled to give 5.46 g (89%) of the desired THP-hydroxylamine as a clear colorless oil with b.p. = 70 °C (10 mm Hg). Note: Compound crystallizes upon cooling in freezer under argon. TLC (1:1) EtOAc-Hex, R_f 0.31, UV + PMA.

5 B. N-(Tetrahydropyran-2-yloxy)cyclohexaneacetamide

To a 0 °C solution of cyclohexanemethylcarboxylic acid (1.0 g, 7.0 mmol) in 40 ml of CH₂Cl₂ under argon was added O-tetrahydropyran-2-ylhydroxylamine (1.64 g, 2.0 eq.), 1-hydroxybenzotriazole (1.14 g, 1.2 eq.), N,N'-dicyclohexylcarbodiimide (1.73 g, 1.2 eq.) sequentially. After 0.5 hour at 0 °C the solution was allowed to warm to room temperature and stir under argon for 6 hours. The solution was filtered, concentrated *in vacuo* to yield a white solid which was chromatographed on LPS-1 silica gel eluting with 1:1 hexane/EtOAc. Product containing fractions were evaporated to give title compound, a white solid 1.05 g (62%) after trituration with hexane.

15 C. N-(Phenylmethyl)-N-(tetrahydropyran-2-yloxy)cyclohexaneacetamide

To a stirring solution of the compound of Part B (500 mg, 2.1 mmol) under argon in 10 ml of dry toluene was added NaH (1.1 eq., 55 mg). The mixture was allowed to stir for 30 minutes then benzyl bromide (0.74 ml, 3.0 eq.) was added. The mixture was heated to reflux and allowed to stir for 2 hours. The reaction was cooled and diluted with EtOAc and partitioned over 5% KHSO₄. The organic phase was washed with brine, dried over anhydrous MgSO₄ and evaporated to yield yellow oil which was chromatographed on LPS-1 silica gel eluting with 9:1 hexane:EtOAc. Product containing fractions were evaporated to give title compound (560 mg, 82%) as a pale yellow oil. TLC (9:1) hexane:EtOAc. R_f = 0.19, UV + CeMo.

25 D. N-Hydroxy-N-(phenylmethyl)cyclohexaneacetamide

To a stirring solution of the compound of Part C (560 mg, 1.7 mmol) in 10 ml of CH₃OH under argon was added pyridinium-p-toluenesulfonate (510 mg; 1.2 eq.). The solution was heated to 60 °C in an oil bath for 24 hours. The solution was diluted with EtOAc and washed with 10 ml of brine, diluted with 10 ml of water. The organic layer was washed with brine (10 ml) and dried over MgSO₄ (anhydrous) and reduced *in vacuo* to yield an off-white solid which was recrystallized from hexane/EtOAc to give title product (380 mg) (91%) as a white solid with m.p. 83-85 °C. TLC (1:1) hexane-EtOAc; R_f = 0.45, UV + CeMo. Anal Calcd for C₁₅H₂₁NO₂•0.1MH₂O: C, 72.28; H, 8.49; N, 5.51. Found: C, 72.28; H, 8.49; N, 5.51. M.P. 83-85.5 °C.

Example 5

N-Hydroxy-N-(phenylmethyl)benzenebutanamide

40 A. N-(Tetrahydropyran-2-yloxy)benzenebutanamide

To a 0 °C solution of 3-phenylpropyl carboxylic acid (1.0 g, 6.1 mmol) in 40 ml of CH₂Cl₂ under argon was added H₂N-OTHP (1.43 mg, 2.0 eq.), 1-hydroxybenzotriazole (987 mg, 1.2 eq.), N,N'-dicyclohexylcarbodiimide (1.51 g, 1.2 eq.) sequentially. After 0.5 hour at 0 °C, the solution was allowed to warm to room temperature and stir under argon for 4 hours. The solution was filtered, concentrated *in vacuo* to yield title compound as a white solid, wt. 1.13 g (71%).

B. N-(Phenylmethyl)-N-(tetrahydropyran-2-yloxy)benzenebutanamide

50 To a stirring solution of Part A compound (520 mg, 197 mmol) under argon in 10 ml of dry toluene was added NaH (1.1 eq., 52 mg). The mixture was allowed to stir for 30 minutes, then benzyl bromide (0.71 ml, 3.0 eq.) was added. The mixture was heated to reflux and allowed to stir for 2 hours. The reaction was cooled and diluted with EtOAc and partitioned over 5% KHSO₄. The organic phase was washed with brine, dried over anhydrous Na₂SO₄ and evaporated to yield a yellow oil which was chromatographed on LPS-1 silica gel eluting with 4:1 hexane: EtOAc. Product containing fractions were evaporated to give title compound (550 mg, 79%) as a pale yellow oil. TLC (9:1) hexane:EtOAc. R_f = 0.12, UV + PMA.

C. N-Hydroxy-N-(phenylmethyl)benzenebutanamide

To a stirring solution of Part B compound (550 mg, 1.55 mmol) in 10 ml of CH_3OH under argon was added pyridinium-p-toluenesulfonate (391 mg, 1.0 eq.). The solution was heated to 60°C in an oil bath for 48 hours. The solution was diluted with EtOAc and washed with 10 ml of brine, diluted with 10 ml of water. The organic layer was washed with brine (10 ml) and dried over MgSO_4 (anhydrous) and reduced in *vacuo* to yield an off-white solid, which was recrystallized from hexane/EtOAc to give title product (320 mg) (87%) as a white solid with m.p. $72\text{--}74^\circ\text{C}$. TLC (1:1) hexane-EtOAc; $R_f = 0.38$, UV + CeMo. Products streaks to baseline.

Anal Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_2\bullet 0.11\text{M H}_2\text{O}$: C, 75.23; H, 7.14; N, 5.16
Found: C, 75.23; H, 7.11; N, 5.20
M.P. 72-73.5 °C.

Example 6

N-Hydroxy-N-pentylbenzenebutanamide

15 A. N-(Tetrahydropyran-2-yloxy)benzenebutanamide

To a 0°C of 3-phenylpropyl carboxylic acid (1.0 g, 6.1 mmol) in 20 ml of CH_2Cl_2 under argon was added $\text{H}_2\text{N-OTHP}$ (1.43 g, 2.0 eq.), 1-hydroxybenzotriazole (987 mg, 1.2 eq.), N,N'-dicyclohexylcarbodiimide (1.51 g, 1.2 eq.) sequentially. The solution was allowed to warm to room temperature and stir under argon for 4 hours. The solution was filtered, concentrated in vacuo, diluted with EtOAc, and refiltered. Concentration in vacuo gave a golden oil which was chromatographed on LPS-1 silica gel eluting with 1:1 hexane/EtOAc. Product containing fractions were concentrated in vacuo as a white solid which was triturated with hexane (2X) to yield title compound, wt. 1.13 g (71%).

25 B. N-Pentyl-N-(tetrahydropyran-2-yloxy)-benzenebutanamide

To a stirring solution of Part A compound (610 mg, 2.3 mmol) under argon in 15 ml of dry toluene was added NaH (1.1 eq., 61 mg). The mixture was allowed to stir for 30 minutes then pentyl bromide (0.86 ml, 3.0 eq.) was added. The mixture was heated to reflux and allowed to stir overnight. The reaction was cooled and diluted with EtOAc and partitioned over 5% KHSO_4 . The organic phase was washed with brine, dried over anhydrous MgSO_4 and evaporated to yield yellow oil which was chromatographed on LPS-1 silica gel eluting with (8:2) hexane:EtOAc. Product containing fractions were evaporated to give title compound (480 g) as an oil. TLC (1:1) hexane:EtOAc. $R_f = 0.55$, UV + PMA.

35 C. N-Hydroxy-N-pentylbenzenebutanamide

To a stirring solution of Part B compound (480 mg, 1.44 mmol) in 15 ml of CH_3OH under argon was added pyridinium-p-toluenesulfonate (444 mg, 1.0 eq.). The solution was heated to 60°C in an oil bath overnight. The solution was diluted with EtOAc and washed with 10 ml of brine diluted with 10 ml of water. The organic layer was washed with brine (10 ml) and dried over Na_2SO_4 (anhydrous) and reduced in *vacuo* to yield an oil which was chromatographed on LPS-1 silica gel eluting with 1:1 hexane/EtOAc. Product containing fractions were evaporated to give title product 360 mg (~100%). TLC (1:1) hexane/EtOAc $R_f = 0.29$, UV + PMA. Product streaks to baseline.
Anal Calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_2\bullet 0.22\text{M H}_2\text{O}$: C, 71.10; H, 9.32; N, 5.53
Found: C, 71.10; H, 9.11; N, 5.20

Example 7

N-Hydroxy-N-methyldecaneamide

50 A. N-Benzyl-1-decylamide

To a stirred solution of the 1-decetyl carboxylic acid (2.00 g, 11.64 mM) in dry CH_2Cl_2 : C, 71.10; (35 ml) is added 1-hydroxybenzotriazole (1.89 g, 13.97 mM, 1.2 eq.) and N,N'-dicyclohexylcarbodiimide (2.88 g, 13.97 mM, 1.2 eq.). After one hour at room temperature under argon, O-benzylhydroxylamine hydrochloride (4.64 g, 29.1 mM, 2.5 eq.) and Et_3N (4.06 ml, 29.1 mM, 2.5 eq.) are added and the mixture stirred for an additional two hours. The crude mixture is filtered (2X), evaporated, taken up in ethyl acetate, filtered again and then washed successively with 5% KHSO_4 , saturated NaHCO_3 , and brine. Concentration in *vacuo* leaves a solid which is flash chromatographed on LPS-1 silica gel eluting with (9:1) H x-EtOAc. Product

containing fractions are concentrated in vacuo to a white solid which is recrystallized once from ethyl acetate-hexane to give desired title product.

B. N-Benzyl-N-methyl-1-decenylamide

5

To a solution of the title A benzylhydroxamate (496 mg, 1.80 mM) in dry toluene (5 ml) is added prewashed NaH (45 mg, 1.80 mM) and the mixture stirred for 20 minutes at room temperature under argon. Excess methyl iodide (0.313 ml, 4.92 mM, 3 eq) is added and the mixture is refluxed for 5 hours, then cooled and partitioned between 5% KHSO₄ and ethyl acetate. The organic phase is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a yellow oil which was chromatographed on Whatman LPS-1 silica gel eluting with (3:2) pet ether-ether. Product containing fractions are evaporated to give the title N-methylated product.

C. N-Hydroxy-N-methyldecaneamide

15

Argon is bubbled through a solution of the title B N-methylhydroxamate (600 mg) in CH₃OH (10 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (100 mg, 15% by weight) and stirring under H₂ for 2 hours. The mixture is then filtered through Celite, evaporated, taken up in EtOAc, filtered through a small plug of Whatman LPS-1 silica gel and evaporated to an off-white crystalline solid. Recrystallization from EtOAc-Hex gives desired title product.

Example 8

4-[1-Decenylcarbonyl]hydroxyamino]butanoic acid

25 A. N-(Tetrahydropyran-2-yloxy)-1-decenylamide

To a solution of 1-decenyliccarboxylic acid (0.66 g, 3.84 mM) in dry CH₂Cl₂ (15 ml) is added 1-hydroxybenzotriazole (623 mg, 4.61 mM, 1.2 eq) and DCC (951 mg, 4.61 mM, 1.2 eq) and the mixture stirred for one hour under argon at room temperature. O-THP-hydroxylamine (900 mg, 7.68 mM, 2 eq) is added and the mixture stirred for 3 hours at room temperature. The mixture is filtered, evaporated, taken up in ethyl acetate, filtered again, evaporated and chromatographed on Whatman LPS-1 silica gel eluting with (8:2) Hex-EtOAc. Product containing fractions are evaporated to give title coupled product.

35 B. 4-[1-Decenylcarbonyl]tetrahydropyran-2-yloxyamino]butanoic acid, ethyl ester

35

Prewashed NaH (70 mg, 2.9 mM, 1.2 eq) is added to a solution of the title A THP-hydroxamate (622 mg, 2.42 mM) in dry toluene (10 ml) and the mixture stirred at room temperature under argon for 15 minutes. Ethyl-4-iodobutyrate (1.76 g, 7.26 mM, 3 eq) is added and the mixture is refluxed overnight. The mixture is partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is run through neutral alumina (act = 1) to remove any remaining starting material eluting with (8:2) Hex-Acetone. Product fractions are evaporated and then chromatographed on Whatman LPS-1 silica gel eluting with (95:5) Hex-Acetone. Product fractions are evaporated to give the desired title N-alkylated product.

45 C. 4-[1-Decenylcarbonyl]hydroxyamino]butanoic acid, ethyl ester

A stirred mixture of the title B O-THP hydroxamate (816 mg, 2.20 mM) in (3:2:2) HOAc:THF:H₂O (6 ml) is heated at 55 °C overnight under argon. The mixture is then carefully partitioned between saturated NaHCO₃ and EtOAc, the organic layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to give the desired title hydroxamic acid.

D. 4-[1-Decenylcarbonyl]hydroxyamino]butanoic acid

To a solution of the title C crude ethyl ester (879 mg) in dioxane (10 ml) is added a 1.0 N LiOH solution (4.4 ml) and the mixture stirred for 1.5 hours at room temperature under argon. The mixture is then partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to a solid. One recrystallization from EtOAc-Hex gives the desired hydroxamic acid.

Example 94-[(Decylcarbonyl)hydroxyamino]butanoic acid, ethyl ester

Argon was bubbled through a solution of the Example 8 title C hydroxamate (357 mg, 1 mM) in 5 absolute EtOH (15 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (59 mg) and shaking the mixture under H₂ on a Parr apparatus for 7 hours. The mixture is filtered through a layered plug of Celite and Whatman LPS-1 silica gel and evaporated to give the desired title hydroxamic acid.

Example 1010 4-[(2-Decylcarbonyl)hydroxyamino]butanoic acid, dilithium salt

To a stirred solution of the Example 9 methyl ester (357 mg, 1 mM) in dioxane (4 ml) is added a 1.0N LiOH solution (2.6 ml, 2.6 mM) and the mixture stirred under argon for 3 hours. The mixture is diluted with H₂O, extracted with ether (to remove a non-polar impurity), the aqueous layer acidified to pH 2 with 1.0N 15 HCl and then re-extracted with ethyl acetate. The organic phase is washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil.

The crude oil is dissolved in 1.0N LiOH (3 ml) and chromatographed on HP-20 eluting with a gradient of neat H₂O → (50:50) H₂O-CH₃CN. Product containing fractions are combined and lyophilized to give the desired title product.

20

Example 114-[(Decylcarbonyl)hydroxyamino]butanoic acid, ethyl esterA. 4-[[1-Decenyl]carbonyl]benzylxyamino]butanoic acid, ethyl ester

25

Prewashed sodium hydride (188 mg, 7.5 mM, 1.1 eq.) is added to a solution of hydroxamate prepared in Example 7 Part A (2.00 g, 6.84 mM) in dry toluene (14 ml) and the mixture stirred at room temperature under argon for 15 minutes. Ethyl-4-iodobutyrate (3.31 g, 13.68 mM, 2.0 eq.) is then added and the mixture refluxed overnight. The crude mixture is cooled, partitioned between 5% KHSO₄ and EtOAc, the organic 30 layer washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an oil. The oil is dissolved in CH₂Cl₂ and flash chromatographed on Whatman LPS-1 silica gel eluting with (3:2) pet ether-ether. Product containing fractions are evaporated to give the desired title alkylated product.

B. 4-[(Decylcarbonyl)hydroxyamino]butanoic acid, ethyl ester

35

Argon is bubbled through a solution of the title A hydroxamate (407 mg, 1 mM) in absolute ethanol (10 ml) for 5 minutes before adding 20% palladium hydroxide on carbon (58 mg), and stirring under H₂ for 4 hours. The mixture is then filtered through a layered plug of Celite over LPS-1 silica gel, evaporated to a solid and recrystallized from EtOAc-Hex to give the desired title hydroxamic acid

40

Example 124-[[1-Decenyl]carbonyl]methoxyamino]butanoic acid, dicyclohexylamine salt(1:1)A. N-methoxy-1-decenylamide

45

To a solution of 1-decenyl carboxylic acid (1.32 g, 7.68 mM) in dry CH₂Cl₂ (20 ml) is added 1-hydroxybenzotriazole (1.25 g, 9.22 mM, 1.2 eq.) and N,N'-dicyclohexylcarbodiimide (1.90 g, 9.22 mM, 1.2 eq.) and the mixture stirred for 1 hour at room temperature. Methoxylamine hydrochloride (1.28 g, 15.36 mM, 2 eq.) and triethylamine (2.14 ml, 15.36 mM, 2 eq.) are added, the mixture stirred for 3 hours at room 50 temperature, then filtered, evaporated, taken up in ethyl acetate and filtered again. The organic phase is washed successively with 5% KHSO₄, saturated NaHCO₃ and brine, then dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude oil is flash chromatographed on LPS-1 silica gel eluting with (7:3) hexane-ethyl acetate. Product containing fractions are evaporated to give the desired title product.

55

B. 4-[[1-Decenyl]carbonyl]methoxyamino]butanoic acid, ethyl ester

To a solution of the title A methyl hydroxamate (328 mg, 1.52 mM in dry toluene (6 ml) is added prewashed NaH (38 mg, 1.52 mM) and the mixture stirred for 20 minutes at room temperature. Ethyl-4-

iodobutyrate (668 mg, 2.76 mM) is added and the mixture is refluxed overnight under argon. The mixture is cooled, partitioned between 5% KHSO_4 and ethyl acetate and the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. The crude oil is flash chromatographed on LPS-1 silica gel luting with (3:2) petroleum ether-Et₂O. Product containing fractions are evaporated to give the desired title N-alkylated product.

5 C. 4[[1-Decenyl]carbonyl]methoxyamino]butanoic acid

To a solution of the title B ethyl ester (660 mg, 2 mM) in dioxane (10 ml) is added 1.0N LiOH (2.20 ml) 10 and the mixture stirred at room temperature under argon for two hours. The mixture is then partitioned between 5% KHSO_4 and ethyl acetate, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. Crude oil is flash chromatographed on LPS-1 silica gel eluting successively with (85-15) Hex-Acetone and (95-5) $\text{CH}_2\text{Cl}_2\text{-CH}_3\text{OH}$. Product containing fractions are evaporated to give the title acid.

15

D. 4[[1-Decenyl]carbonyl]methoxyamino]butanoic acid, dicyclohexylamine salt(1:1)

The dicyclohexylamine salt is prepared by dissolving the title C acid in EtOAc (1 ml) and treating it with dicyclohexylamine (126 μl , 1.1 eq.). The mixture is evaporated and then crystallized from cold petroleum ether to give the title methyl hydroxamate as the dicyclohexylamine salt.

Example 13

N-(4-Amino-4-oxobutyl)-4-decyl-N-hydroxydecaneamide

25 A. 4[[1-Decenyl]carbonyl]benzyloxyamino]butanoic acid

To a solution of the ethyl ester prepared as described in Example 11 Part A (814 mg, 2 mM) in dioxane (5 ml) is added 1.0N LiOH (2.3 ml) and the mixture stirred for 3 hours under argon at room temperature. The mixture is then partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to give the title acid.

B. N-(4-Amino-4-oxobutyl)-4-(1-deceny)-N-benzyloxydecaneamide

To a solution of the title A acid (379 mg, 1 mM) and Et₃N (181 μl , 1.3 mM) in dry CH_3CN (5 ml) is 35 added isobutylchloroformate (169 μl , 1.3 mM) and the mixture stirred for 1 hour at room temperature under argon. Concentrated NH_4OH (3 ml) is added dropwise, the mixture is stirred for 30 minutes, then it is partitioned between 1.0N HCl and EtOAc. The organic layer is washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. The crude oil is chromatographed on alumina (neutral activity = 2) with (1:1) EtOAc-Hex and (9:1) $\text{CH}_2\text{Cl}_2\text{-CH}_3\text{OH}$ followed by a chromatography on Whatman LPS-1 silica gel 40 eluting with neat EtOAc. Product containing fractions are evaporated to give the title amide.

C. N-(4-Amino-4-oxobutyl)-4-decyl-N-hydroxydecaneamide

Argon is bubbled through a solution of the title B hydroxamate (290 mg) in CH_3OH (5 ml) for 5 minutes 45 before adding 20% palladium hydroxide on carbon (35 mg, 12% by weight) and stirring under H_2 for 2 hours. The mixture is filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO_4 powder and evaporated to an off-white solid. Two recrystallizations (from EtOAc-Hex, then acetone-Hex) give the title amide.

50 Example 14

5-[(Decylcarbonyl)hydroxyamino]pentanoic acid

A. 5[[1-Decenyl]carbonyl]benzyloxyamino]pentanoic acid, ethyl ester

55 Prewashed NaH (51 mg, 2.11 mM, 1.1 eq.) is added to a solution of the hydroxamate prepared as described in Example 7 Part A (562 mg, 1.92 mM) in dry toluene (10 ml) and the mixture stirred for 20 minutes at room temperature under argon. Ethyl-5-iodovalerate (1.48 g, 5.76 mM, 3 eq.) is added and the mixture refluxed overnight. The mixture is then partitioned between 5% KHSO_4 and EtOAc, the organic

layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to an oil. The remaining starting material is removed by chromatography on neutral alumina (act. = 1) eluting with (1:1) petroleum-ether. Product fractions are evaporated, then flash chromatographed on Whatman LPS-1 silica gel eluting with (3:2) petroleum ether-ether. Product fractions are evaporated to give the title N-alkylated product.

5

B. 5-[(4-Decylcarbonyl)hydroxyamino]pentanoic acid, ethyl ester

Argon is bubbled through a solution of the title A hydroxamate (421 mg) in methanol (10 ml) for 5 minutes, then 20% palladium hydroxide on carbon (15 mg) is added and the mixture stirred under H_2 for 1 hour. The mixture is filtered through Celite, evaporated, taken up in ethyl acetate, filtered through powder MgSO_4 and evaporated to give the desired title hydroxamic acid.

C. 5-[(Decylcarbonyl)hydroxyamino]pentanoic acid

15 To a solution of the title B ethyl ester (331 mg, 1 mM) in dioxane (8 ml) is added 1.0 N LiOH (2.9 ml) and the mixture stirred under argon at room temperature for 40 minutes. The mixture is then partitioned between 5% KHSO_4 and EtOAc, the organic phase washed with brine, dried over anhydrous Na_2SO_4 and evaporated to a solid. One recrystallization from EtOAc-Hex gives desired title acid.

20

Example 15
(N-Hydroxydecaneamido)acetic acid

A. Decyl carboxylic acid

25 Argon is bubbled through a solution of 1-decylcarboxylic acid (1.6 g) in CH_3OH (20 ml) for 5 minutes. 10% Palladium on carbon is added and the mix is shaken on a Parr apparatus for 4 hours under H_2 . The mixture is filtered through Celite and evaporated to give the desired title saturated acid.

B. N-Benzyl oxydecaneamide

30

To a solution of the title A acid (590 mg, 3.43 mM) in dry CH_2Cl_2 (15 ml) is added 1-hydroxybenzotriazole (557 mg, 4.12 mM, 1.2 eq.) and N,N'-dicyclohexylcarbodiimide (850 mg, 4.12 mM, 1.2 eq.) and the mixture stirred at room temperature under argon for 1 hour. Triethylamine (1.20 ml, 8.58 mM, 2.5 eq.) and O-benzylhydroxylamine hydrochloride (1.37 g, 8.58 mM, 2.5 eq.) are then added and the mixture stirred for 3 hours at room temperature. The mixture is filtered, evaporated, taken up in ethyl acetate and washed successively with 5% KHSO_4 and brine then dried over anhydrous Na_2SO_4 and evaporated to a white solid. Crude solid is flash chromatographed on Whatman LPS-1 silica gel eluting with (9:1) hexane-EtOAc. Product containing fractions are evaporated to give the desired title benzylhydroxamate.

40

C. N-(3-Prop-1-enyl)-N-benzyl oxy decaneamide

To a solution of the title B benzylhydroxamate (399 mg, 1.36 mM) in dry toluene (6 ml) is added prewashed NaH (36 mg, 1.50 mM, 1.1 eq.) and the solution stirred at room temperature for 20 minutes before adding allyl bromide (294 μl , 3.4 mM, 2.5 eq.) and refluxing overnight. The mixture is cooled, partitioned between 5% KHSO_4 and EtOAc, the organic layer washed with brine, dried over anhydrous Na_2SO_4 and evaporated to a yellow oil. Crude oil is chromatographed on neutral alumina (act. = 1) eluting with (1:1) petroleum ether-ether. Product fractions are evaporated to give the title N-alkylated product.

50

D. N-Benzyl oxydecaneamido)acetic acid, methyl ester

The title C N-alkylbenzylhydroxamate (3.34 g, 10 mM) is dissolved in EtOAc, (16 ml) cooled to -78°C and purged with O_2 before bubbling ozone through the solution until a pale blue color persisted. Excess ozone is purged with bubbling N_2 , then the ozonide solution is treated with Jones reagent (1.0 ml) at -78°C . The mixture is allowed to warm to room temperature, diluted with EtOAc and the organic phase washed successively with H_2O and brine, then dried over anhydrous Na_2SO_4 and evaporated to a crude oil.

The crude oil is dissolved in Et_2O (10 ml), cooled to 0°C (ice bath) and treated with an ethereal solution of diazomethane. The mixture is evaporated, and chromatographed on Whatman LPS-1 silica gel eluting with (9:1) Hex-EtOAc. Product fractions are evaporated to give the desired title methyl ester.

E. (N-Hydroxydecaneamido)acetic acid, methyl ester

5 Argon is bubbled through a solution of the title D benzylhydroxamate (270 mg) in CH₃OH (8 ml) for 5 minutes, then 20% palladium hydroxide on carbon (32 mg, 12% by weight) is added and the mixture stirred for 1 hour under H₂. The mixture is filtered through Celite, evaporated, taken up in EtOAc, filtered through anhydrous MgSO₄ and evaporated to give the title E hydroxamic acid.

F. (N-Hydroxydecaneamide)acetic acid

10 To a solution of the title E methyl ester (274 mg, 1 mM) is dissolved in dioxane (6 ml) is added 1.0N LiOH (2.16 ml, 2.16 mM) and the mixture stirred for 20 minutes at room temperature under argon. The mixture is partitioned between 5% KHSO₄ and EtOAc, the organic phase washed with brine, dried over anhydrous Na₂SO₄ and evaporated to an off-white solid. One recrystallization from EtOAc-Hex gives the desired title acid.

15

Example 16N-Hydroxy-N-propyl[1,1'-biphenyl]-4-acetamide

20 Following the procedure of Example 1 except substituting N-propylhydroxylamine for N-methylhydroxylamine, the title compound is obtained.

Example 17N-Hydroxy-N-(phenylmethyl)[1,1'-biphenyl]-4-acetamide

25 Following the procedure of Example 1 except substituting N-(phenylmethyl)hydroxylamine for N-methylhydroxylamine, the title compound is obtained.

Example 18N-Hydroxy-N-phenyl[1,1'-biphenyl]-4-acetamide

30

Following the procedure of Example 1 except substituting N-(phenyl)hydroxylamine for N-methylhydroxylamine, the title compound is obtained.

Example 19N-Cyclohexyl-N-hydroxycyclohexaneacetamide

Following the procedure of Example 4 except substituting cyclohexyl iodide for benzyl bromide, the title compound is obtained.

40

Example 20N-Hydroxy-N-propylcyclohexaneacetamide

Following the procedure of Example 4 except substituting propyl iodide for benzyl bromide, the title compound is obtained.

45

Example 21N-Hydroxy-N-butylbenzenebutanamide

50 Following the procedure of Example 5 except substituting butyl iodide for benzylbromide, the title compound is obtained.

Example 22N-Hydroxy-N-i-butylbenzenebutanamide

55 Following the procedure of Example 5 except substituting i-butyl iodide for benzyl bromide, the title compound is obtained.

Example 23

N-Hydroxy-N-pentylbenzenebutanamide

Following the procedure of Example 5 except substituting pentyl iodide for benzyl bromide, the title compound is obtained.

5

Example 24N-Hydroxy-N-hexylbenzenebutanamide

Following the procedure of Example 6 except substituting hexyl iodide for pentyl bromide, the title compound is obtained.

10

Example 25N-Hydroxy-N-phenethylbenzenebutanamide

15 Following the procedure of Example 6 except substituting phenethyl bromide for pentyl bromide, the title compound is obtained.

20

Example 26N-Hydroxy-N-octylbenzenebutanamide

25

Following the procedure of Example 6 except substituting octyl iodide for pentyl bromide, the title compound is obtained.

30

Example 27N-Hydroxy-benzenebutanamide

Following the procedure of Example 6 except eliminating Step B, the title product is obtained.

35

Example 28N-Hydroxy-N-methoxybenzenebutanamide

Following the procedure of Example 3 except substituting N-methoxyamine hydrochloride for N-phenylhydroxyl amine hydrochloride, the title compound is obtained.

40

Example 29N-Ethoxy-N-ethyldecaneamide

Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting ethyl iodide for methyl iodide in Part B, the title compound is obtained.

Example 30N-propoxy-N-butyldecaneamide

45 Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting butyl iodide for methyl iodide in Part B, the title compound is obtained.

50

Example 31N-Pentoxy-N-ethyldecaneamide

Following the procedure of Example 7 except substituting pentoxyamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting ethyl iodide for methyl iodide in Part B, the title compound is obtained.

55

Example 32N-Hexyloxy-N-propyldecaneamide

Following the procedure of Example 7 except substituting hexyloxyamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting propyl iodide for methyl iodide in Part B, the title compound is obtained.

5 **Example 33**
N-Ethoxy-N-benzyldecaneamide

Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting benzyl iodide for methyl iodide in Part B, the title compound is obtained.

Example 34
N-Propoxy-N-phenethyldecaneamide

15 Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting phenethyl iodide for methyl iodide in Part B, the title compound is obtained.

20 **Example 35**
N-Butoxy-N-pentyldecaneamide

Following the procedure of Example 7 except substituting butoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and substituting *n*-pentyl iodide for methyl iodide in Part B, the title compound is obtained.

25 **Example 36**
N-Ethoxydecaneamide

30 Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and eliminating Step B, the title compound is obtained.

Example 37
N-Propoxydecaneamide

35 Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A and eliminating Step B, the title compound is obtained.

Example 38
N-Methoxy-N-methyldecaneamide

40 Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, and eliminating Step C, the title compound is obtained.

45 **Example 39**
N-ethoxy-N-ethyl(1-deceny)amide

Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

50 **Example 40**
N-Propoxy-N-butyl(1-deceny)amide

55 Following the procedure of Example 7 except substituting propoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting butyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

Example 41

N-Pentoxy-N- thyl(1-deceny)amide

Following the procedure of Example 7 except substituting pentoxyamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

Example 42N-Hexyloxy-N-n-propyl(1-deceny)amide

Following the procedure of Example 7 except substituting hexyloxyamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting propyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

Example 43N-Ethoxy-N-benzyl(1-deceny)amide

Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting benzyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

20

Example 44N-Methoxy-N-phenethyl(1-deceny)amide

Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting phenethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

25

Example 45N-Methoxy-N-ethyl(1-deceny)amide

30

Following the procedure of Example 7 except substituting methoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, substituting ethyl iodide for methyl iodide in Part B, and eliminating Step C, the title compound is obtained.

35

Example 46N-Ethoxy(1-deceny)amide

Following the procedure of Example 7 except substituting ethoxylamine hydrochloride for benzylhydroxylamine hydrochloride in Part A, and eliminating Steps B and C, the title compound is obtained.

40

Example 47N-Hydroxy-N-methylundecaneamide

Following the procedure of Example 7 except substituting 1-undecenylcarboxylic acid for 1-decenylcarboxylic acid in Part A, the title compound is obtained.

Example 48N-Hydroxy-N-methylhexylamide

Following the procedure of Example 7 except substituting 1-hexenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

Example 49N-Hydroxy-N-methylheptaneamide

55

Following the procedure of Example 7 except substituting 1-heptenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

Example 50

N-Hydroxy-N-methyloctaneamide

5 Following the procedure of Example 7 except substituting 1-octenylcarboxylic acid for 1-decenylic acid, the title compound is obtained.

Example 51

N-Hydroxy-N-methylnonaneamide

10 Following the procedure of Example 7 except substituting 1-nonenylcarboxylic acid for 1-decenylic acid, the title compound is obtained.

Example 52

N-Hydroxy-N-methyldodecaneamide

15 Following the procedure of Example 7 except substituting 1-dodecenylcarboxylic acid for 1-decenylic acid, the title compound is obtained.

Example 53

20 N-Hydroxy-N-methylpentadecaneamide

Following the procedure of Example 7 except substituting 1-pentadecenylcarboxylic acid for 1-decenylic acid, the title compound is obtained.

25 Example 54

N-Hydroxy-N-methylpropaneamide

Following the procedure of Examples 7 and 13 except substituting acrylic acid for 1-decenylic acid, the title compound is obtained.

30

Example 55

N-Hydroxy-N-methyl(1-hexenyl)amide

35 Following the procedure of Example 8 except substituting (1-hexenyl)carboxylic acid for (1-decenylic)carboxylic acid in Part A and substituting methyl iodide for ethyl-4-iodobutyrate in Part B, the title compound is obtained.

Example 56

4-[(Decylcarbonyl)hydroxyamino]butanoic acid

40

Following the procedure of Example 7 except substituting ethyl-4-iodobutyrate for methyl iodide, the title compound is obtained.

Example 57

45 5-[(1-Decenyl)carbonyl]hydroxyamino]pentanoic acid

Following the procedure of Example 8 except substituting ethyl-5-iodovalerate for ethyl-4-iodobutyrate, the title compound is obtained.

50 Example 58

5-[(1-Heptenyl)carbonyl]methoxyamino]pentanoic acid

55 Following the procedure of Example 12 except substituting 1-heptenylcarboxylic acid for 1-decenylic acid, and ethyl-5-iodovalerate for ethyl-4-iodobutyrate and eliminating the addition of dicyclohexylamine, the title compound is obtained.

Example 59

4-[(1-Noneyl)carbonyl]methoxyamino]butanoic acid

Following the procedure of Example 12 except substituting 1-nonenylcarboxylic acid for 1-decenylcarboxylic acid and eliminating the addition of dicyclohexylamine, the title compound is obtained.

Example 60

5-[(1-Undecenyl)benzoyl]methoxyamino]pentanoic acid

Following the procedure of Example 12 except substituting 1-undecenylcarboxylic acid for 1-decenylcarboxylic acid and ethyl-5 iodovalerate for ethyl-4-iodobutyrate and eliminating the addition of dicyclohexylamine, the title compound is obtained.

10

Example 61

4-[(1-Tridecyl)carbonyl]methoxyamino]butanoic acid

Following the procedure of Example 12 except substituting 1-tridecenylcarboxylic acid for 1-decenylcarboxylic acid, and eliminating the addition of dicyclohexylamine, the title compound is obtained.

15

Example 62

3-[(1-Hexenyl)carbonyl]ethoxyamino]pentanoic acid

20 Following the procedure of Example 12 except substituting 1-hexenylcarboxylic acid for 1-decenylcarboxylic acid, ethoxylamine hydrochloride for methoxylamine hydrochloride and ethyl-3 iodovalerat for ethyl-4-iodobutyrate, and eliminating the addition of dicyclohexylamine, the title compound is obtained.

25

Example 63

4-[(1-Octadecenyl)carbonyl]hexyloxyamino]butanoic acid

Following the procedure of Example 12 except substituting 1-octadecenylcarboxylic acid for 1-decenylcarboxylic acid and hexyloxyamine hydrochloride for methoxylamine hydrochloride, and eliminating the addition of dicyclohexylamine, the title compound is obtained.

30

Example 64

(N-Hydroxydodecaneamido)acetic acid

35 Following the procedure of Example 15 except substituting 1-dodecenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

40

Example 65

(N-Hydroxyhexaneamido)acetic acid

45 Following the procedure of Example 15 except substituting 1-hexenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

50

Example 66

(N-Hydroxytetradecaneamido)acetic acid

55 Following the procedure of Example 15 except substituting 1-tetradecenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

60

Example 67

(N-hydroxylheptaneamido)acetic acid

Following the procedure of Example 15, except substituting 1-heptenylcarboxylic acid for 1-decenylcarboxylic acid, the title compound is obtained.

65

Example 68

N-(4-Amino-4-oxobutyl)-N-methoxy octaneamide

Following the procedure of Example 13 except substituting 1-octenylcarboxylic acid for 1-decenylcar-

boxylic acid and methoxylamine hydrochloride for benzyloxyamine hydrochloride (in Example 7 Part A), the title compound is obtained.

Example 69

5 N-(4-Amino-4-oxobutyl)-N-ethoxy tridecaneamide

Following the procedure of Example 13 except substituting 1-tridecenyliccarboxylic acid for 1-decenyliccarboxylic acid and ethoxylamine hydrochloride for benzyloxyamine hydrochloride (in Example 7 Part A), the title compound is obtained.

10

Example 70

15 N-(4-Amino-4-oxobutyl)-N-methoxy decaneamide

Following the procedure of Example 13 except substituting methoxylamine hydrochloride for benzyloxyamine hydrochloride (in Example 7, Part A), the title compound is obtained.

Example 71

20 N-(4-Amino-4-oxobutyl)-N-hydroxy undecaneamide

20

Following the procedure of Example 13 except substituting 1-undecenyliccarboxylic acid for 1-decenyliccarboxylic acid, the title compound is obtained.

Example 72

25 N-(4-Amino-4-oxobutyl)-N-hydroxy nonadecaneamide

25

Following the procedure of Example 13 except substituting 1-nonadecenyliccarboxylic acid for 1-decenyliccarboxylic acid, the title compound is obtained.

Example 73

30 N-Hydroxy(1-deceny)amide

To a solution of compound prepared as described in Example 8 Part A (257 mg, 1 mmol) in 6 ml of CH_3OH under argon is added pyridinium 4-toluenesulfonate (210 mg, 1.0 eq.). The mixture is heated to 55 °C and stirred for 4 hours. The solution is diluted with ether and washed with $\frac{1}{2}$ saturated sodium chloride (20 ml) and brine (10 ml). The organic layer is dried over anhydrous MgSO_4 and reduced to yield a solid. Recrystallization from hexane/EtOAc gives title compound.

Example 74

35 N-Hydroxydecaneamide

40

Following the procedure of Example 7 Part C except substituting the Example 73 compound for the Example 7 Part B compound, the title compound is obtained.

Example 75

45 N-Hydroxy(1-Tetradecenyl)amide

Following the procedure of Example 73 except substituting 1-tridecenyliccarboxylic acid for 1-decenyliccarboxylic acid in Example 7, Part A, the title compound is obtained.

50

Example 76

55 N-Hydroxy-N-allyl-benzenebutanamide

Following the procedure of Example 6 except substituting allyl bromide for pentyl bromide, the title compound is obtained.

55

Example 77

55 N-Hydroxy-N-cyclohexylbenzenebutanamide

Following the procedure of Example 3 except substituting N-cyclohexylhydroxylamine hydrochloride for N-phenylhydroxylamine hydrochloride, the title compound is obtained.


Example 78
5 N-Hydroxy-N-methyl-4-cyclohexylbutaneamide

Following the procedure of Example 3 except substituting 3-cyclohexylpropylcarboxylic acid for 3-phenylpropylcarboxylic acid in Part A, the title compound is obtained.

10 Claims


1. Use of a compound having the structure

15



20 wherein R¹ is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl, or

25



wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C₁-C₄-alkylamino or C₁-C₄-dialkyamino;

R² is hydrogen or lower alkyl;

30 R³ is C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower alkoxy, lower alkenyloxy, aryl-alkoxy, or cycloalkyloxy; and

m is 1 to 5;

or such a compound in pharmaceutically acceptable monobasic and dibasic salt form,

35 wherein "lower alkyl" or "alkyl" (alone or as part of another group) means straight and branched chain radicals of up to 12 carbons (unless otherwise indicated), as well as such groups including a halo-substituent, such as F, Br, Cl or I or CF₃, an alkoxy substituent, an aryl substituent, an alkyl-aryl substituent, a haloaryl substituent, a cycloalkyl substituent, an alkylcycloalkyl substituent, hydroxy, an alkylamino substituent, an alkanoylamino substituent, an arylcarbonylamino substituent, a nitro substituent, a cyano substituent, or an alkylthio substituent;

40 wherein "cycloalkyl" (alone or as part of another group) means saturated cyclic hydrocarbon groups containing 3 to 12 carbons, which groups may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups, 1 or 2 lower alkoxy groups, an aryl group, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, or 1 or 2 alkylthio groups;

45 wherein "aryl" (alone or as part of another group) means a monocyclic or bicyclic aromatic group containing from 6 to 10 carbons in the ring portion, including substituted phenyl or substituted naphthyl wherein the substituent on either the phenyl or naphthyl may be 1 or 2 lower alkyl groups, 1 or 2 halogens (Cl, Br or F), 1 or 2 lower alkoxy groups, 1 or 2 hydroxyl groups, 1 or 2 alkylamino groups, 1 or 2 alkanoylamino groups, 1 or 2 arylcarbonylamino groups, 1 or 2 amino groups, 1 or 2 nitro groups, 1 or 2 cyano groups, and/or 1 or 2 alkylthio groups.

50 wherein "alkenyl" (alone or as part of another group) means an unsaturated hydrocarbon group having from 3 to 8 carbons (unless otherwise indicated) and a single carbon-carbon double bond;

and wherein "(CH₂)_m" and "(CH₂)_n" include a straight or branched chain radical having from 0 to 5 carbons in the normal chain in the case of "(CH₂)_m" and 1 to 4 carbons in the normal chain in the case of "(CH₂)_n" and may contain one or more lower alkyl or halo substituents;

55 for the manufacture of a medicament for the treatment of allergies.

2. The use as defined in Claim 1 wherein R¹ is alkyl, phenyl or phenylalkyl.

3. The use as defined in Claim 1 wherein R¹ is phenyl or phenylalkyl, R² is H, and R³ is phenyl, biphenyl, or cycloalkyl and m is 1, 2 or 3.

4. The use as defined in Claim 1 wherein the compound is N-hydroxy-N-methyl[1,1-biphenyl]-4-acetamide.

5. The use as defined in Claim 1 wherein the compound is N-(1,1'-dimethylethyl)-N-hydroxy-[1,1'-biphenyl]-4-acetamide.


10. 6. The use as defined in Claim 1 wherein the compound is N-hydroxy-N-phenylbenzenebutanamide.

7. The use as defined in Claim 1 wherein the compound is N-hydroxy-N'(phenylmethyl)cyclohexane acetamide.

15. 8. The use as defined in Claim 1 wherein the compound is N-hydroxy-N-(phenylmethyl)-benzenebutanamide.

9. The use as defined in Claim 1 wherein the compound is N-hydroxy-N-pentylbenzenebutanamide.

20. 10. A compound having the structure



wherein R¹ is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl, aralkyl, or

30

$$(CH_2)_n - \overset{\text{O}}{\underset{\text{C-X}}{\text{C}}}$$

35. wherein n is 1 to 4 and X is hydroxy, alkoxy, amino, C₁-C₄-alkylamino or C₁-C₄-dialkylamino; R² is lower alkyl; R³ is C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, aryl, aryl-alkyl, cycloalkyl, aryl-alkenyl, lower alkoxy, lower alkenyloxy, aryl-alkoxy, or cycloalkyloxy; and m is 1 to 5; or such a compound in pharmaceutically acceptable monobasic and dibasic salt form, wherein "lower alkyl", "alkyl", "cycloalkyl", "aryl", "alkenyl", "(CH₂)_m" and "(CH₂)_n" have the meanings given in claim 1.

40

45

11. The compound as defined in Claim 10 wherein R¹ is alkyl, phenyl or phenylalkyl.

12. N-Hydroxy-N-methyl[1,1'-biphenyl]-4-acetamide.

13. N-(1,1'-Dimethylethyl)-N-hydroxy-[1,1'-biphenyl]-4-acetamide.

50

14. N-Hydroxy-N-phenylbenzenebutanamide.

15. N-Hydroxy-N-(phenylmethyl)cyclohexane acetamide.

16. N-Hydroxy-N-(phenylmethyl)benzenebutanamide.


55

17. N-hydroxy-N-pentylbenzenebutanamide.

Revendications

1. Utilisation d'un composé de formule


5



10 dans laquelle R^1 est l'hydrogène ou un radical alkyle inférieur, aryle, alcényle inférieur, cycloalkyle,

aralkyle, ou

15



où n est un nombre de 1 à 4 et X est un groupement hydroxy, alcoxy, amine, alkylamine en C_1-C_4 ou dialkylamine en C_1-C_4 ;

20 R^2 est l'hydrogène ou un radical alkyle inférieur;

R^3 est un radical alkyle en C_1-C_{20} , alcényle en C_3-C_{20} , aryle, arylalkyle, cycloalkyle, arylalcényle, alcoxy inférieur, alcényloxy inférieur, arylalcoxy, ou cycloalkyloxy; et

m est un nombre de 1 à 5;

25 ou bien d'un tel composé sous forme monobasique ou dibasique pharmaceutiquement acceptable, où "alkyle inférieur" ou "alkyle" (seul ou en tant que partie d'un autre groupement) désigne des radicaux à chaîne droite ou ramifiée ayant jusqu'à 12 atomes de carbone (sauf indication contraire), ainsi que ces mêmes radicaux portant un substituant halogéné tel que F, Br, Cl ou I ou CF_3 , un substituant alcoxy, un substituant aryle, un substituant alkylaryle, un substituant haloaryl, un substituant cycloalkyle, un substituant alkylcycloalkyle, un substituant hydroxy, un substituant alkylamine, un substituant alcanoyle, un substituant arylcarbonylamine, un substituant nitro, un substituant cyano ou un substituant alkylthio;

30 où "cycloalkyle" (seul ou en tant que partie d'un autre groupement) désigne un radical hydrocarbone cyclique saturé contenant de 3 à 12 atomes de carbone, éventuellement substitué par 1 ou 2 radicaux alkyle inférieur, 1 ou 2 radicaux alcoxy inférieur, 1 ou 2 radicaux aryle, 1 ou 2 groupements hydroxy, 1 ou 2 groupements alkylamine, 1 ou 2 groupements alcanoyle, 1 ou 2 groupements arylcarbonylamine, 1 ou 2 groupements amine, 1 ou 2 groupements nitro, 1 ou 2 groupements cyano ou 1 ou 2 groupements alkylthio;

35 où "aryle" (seul ou en tant que partie d'un autre groupement) désigne un radical aromatique monocyclique ou bicyclique contenant de 6 à 10 atomes de carbone dans la partie cyclique, y compris les radicaux phényle ou naphtyle substitués dont le substituant peut être constitué par 1 ou 2 radicaux alkyle inférieur, 1 ou 2 atomes d'halogène (Cl, Br ou F), 1 ou 2 radicaux alcoxy inférieur, 1 ou 2 groupements hydroxyle, 1 ou 2 radicaux alkylamine, 1 ou 2 radicaux alcanoyle, 1 ou 2 radicaux arylcarbonylamine, 1 ou 2 groupements amine 1 ou 2 groupements nitro, 1 ou 2 groupements cyano, et/ou 1 ou 2 radicaux alkylthio;


40 où "alcényle" (seul ou en tant que partie d'un autre groupement) désigne un radical hydrocarboné insaturé ayant de 3 à 8 atomes de carbone (sauf indication contraire) et une seule double liaison carbone-carbone; et

45 où " $(CH_2)_m$ " et " $(CH_2)_n$ " désignent un radical à chaîne droite ou ramifiée ayant de 0 à 5 atomes de carbone dans la chaîne normale dans le cas de " $(CH_2)_m$ " et de 1 à 4 atomes de carbone dans la chaîne normale dans le cas de " $(CH_2)_n$ " et pouvant porter un ou plusieurs substituants alkyle inférieur ou halogénés;

pour la fabrication d'un médicament pour le traitement des allergies.

2. Utilisation selon la revendication 1, dans laquelle R^1 est un radical alkyle, phényl ou phénylalkyle.
3. Utilisation selon la revendication 1, dans laquelle R^1 est un radical phényle ou phénylalkyle, R^2 est l'hydrogène, R^3 est un radical phényle, biphenyle ou cycloalkyle, et m est égal à 1, 2 ou 3.


4. Utilisation selon la revendication 1, dans laquelle le composé est le N-hydroxy-N-méthyl[1,1'-biphénylyl]-4-acétamide.
5. Utilisation selon la revendication 1, dans laquelle le composé est le N-(1,1'-diméthyléthyl)-N-hydroxy-[1,1'-biphénylyl]-4-acétamide.
6. Utilisation selon la revendication 1, dans laquelle le composé est le N-hydroxy-N-phénylbenzènebutanamide.
10. 7. Utilisation selon la revendication 1, dans laquelle le composé est le N-hydroxy-N-(phénylméthyl)-cyclohexane acétamide.
8. Utilisation selon la revendication 1, dans laquelle le composé est le N-hydroxy-N-(phénylméthyl)-benzènebutanamide.
15. 9. Utilisation selon la revendication 1, dans laquelle le composé est le N-hydroxy-N-pentylbenzènebutanamide.
10. 10. Composé ayant pour formule



25

dans laquelle R^1 est l'hydrogène ou un radical alkyle inférieur, aryle, alcényle inférieur, cycloalkyle, aralkyle ou

30



35 où n est un nombre de 1 à 4 et X est un groupement hydroxy, alcoxy, amine, alkylamine en $\text{C}_1\text{-C}_4$ ou dialkylamine en $\text{C}_1\text{-C}_4$;

R^2 est un radical alkyle inférieur;

40 R^3 est un radical alkyle en $\text{C}_1\text{-C}_{20}$, alcényle en $\text{C}_3\text{-C}_{20}$, aryle, arylalkyle, cycloalkyle, arylalcényle, alcoxy inférieur, alcényloxy inférieur, arylalcoxy, ou cycloalkyloxy; et

45

m est un nombre de 1 à 5;

ou bien ce même composé sous la forme d'un sel monobasique ou dibasique pharmaceutiquement acceptable,

ou "alkyle inférieur", "alkyle", "cycloalkyle", "aryle", "alcényle", " $(\text{CH}_2)_m$ " et " $(\text{CH}_2)_n$ " ont les significations qui sont données dans la revendication 1.

45

11. Composé selon la revendication 10, dans lequel R^1 est un radical alkyle, phényle ou phénylalkyle.

12. N-Hydroxy-N-méthyl[1,1'-biphénylyl]-4-acétamide.

50 13. N-(1,1'-Diméthyléthyl)-N-hydroxy[1,1'-biphénylyl]-4-acétamide.

14. N-Hydroxy-N-phénylbenzènebutanamide.

15. N-Hydroxy-N-(phénylméthyl)cyclohexane acétamide.


55 16. N-Hydroxy-N-(phénylméthyl)benzènebutanamide.

17. N-Hydroxy-N-pentylbenzènebutanamide.

Patentansprüche

1. Verwendung einer Verbindung mit der Struktur


5



10

in der R^1 ein Wasserstoffatom, einen Niederalkyl-, Aryl-, Niederalkenyl-, Cycloalkyl- oder Aralkylrest oder die Gruppe

15



20

bedeutet,

in der n 1 bis 4 beträgt und X eine Hydroxygruppe, einen Alkoxyrest, eine Aminogruppe, einen C_1 - C_4 -Alkylaminorest oder einen C_1 - C_4 -Dialkylaminorest bedeutet;

25

R_2 ein Wasserstoffatom oder einen Niederalkylrest darstellt;

R^3 einen C_1 - C_{20} -Alkyl-, C_3 - C_{20} -Alkenyl-, Aryl-, Arylalkyl-, Cycloalkyl-, Arylalkenyl-, Niederalkoxy-, Niederalkenylxy-, Arylalkoxy- oder Cycloalkyloxyrest darstellt; und

30

m 1 bis 5 beträgt oder

einer solchen Verbindung in Form eines pharmazeutisch Verträglichen ein- oder zweibasisigen Salzes, wobei "Niederalkyl" oder "Alkyl" (allein oder als Teil eines anderen Restes), sofern nicht anders bestimmt, einen gerad- oder verzweigtkettigen Rest mit bis zu 12 Kohlenstoffatomen, bedeutet, sowie derartige Reste mit Halogenenresten, wie Fluor-, Brom-, Chlor- oder Jodatome oder die Gruppe CF_3 -, einem Alkoxyresten, einem Arylresten, einem Alkylarylstufenen, einem halogenierten Arylresten, einem Cycloalkylresten, einem Alkylcycloalkylresten, einer Hydroxygruppe, einem Alkylaminoresten, einem Alkanoylaminoresten, einem Arylcarbonylaminoresten, einem Nitroresten, einem Cyanoresten oder einem Alkylthiorest;

35

wobei "Cycloalkyl" (allein oder als Teil eines anderen Restes) einen gesättigten cyclischen Kohlenwasserstoffrest mit 3 bis 12 Kohlenstoffatomen bedeutet, wobei die Reste mit 1 oder 2 Halogenatomen, 1 oder 2 Niederalkylresten, 1 oder 2 Niederalkoxyresten, einem Arylrest, 1 oder 2 Hydroxygruppen, 1 oder 2 Alkylaminoresten, 1 oder 2 Alkanoylaminoresten, 1 oder 2 Aminogruppen, 1 oder 2 Nitrogruppen, 1 oder 2 Cyanogruppen oder 1 oder 2 Alkylthiosten substituiert sein können;

40

wobei "Aryl" (allein oder als Teil eines anderen Restes) einen ein- oder zweikernigen aromatischen Rest mit 6 bis 10 Kohlenstoffatomen im Ringanteil bedeutet, einschließlich substituierter Phenyl- oder substituierter Naphthylgruppen, wobei der Substituent entweder der Phenyl oder der Naphthylgruppe 1 oder 2 Niederalkylreste, 1 oder 2 Halogenatome (Chlor, Brom oder Fluor), 1 oder 2 Niederalkoxyreste, 1 oder 2 Hydroxygruppen, 1 oder 2 Alkylaminreste, 1 oder 2 Alkanoylaminreste, 1 oder 2 Arylcarbonylaminreste, 1 oder 2 Aminogruppen, 1 oder 2 Nitrogruppen, 1 oder 2 Cyanogruppen und/oder 1 oder 2 Alkylthioste bedeuten kann;

45

wobei "Alkenyl" (allein oder als Teil eines anderen Restes), sofern nicht anders bestimmt, einen ungesättigten Kohlenwasserstoffrest mit 3 bis 8 Kohlenstoffatomen und einer einfachen Kohlenstoff-Kohlenstoff-Doppelbindung bedeutet;

50

und wobei die Reste $(CH_2)_m$ und $(CH_2)_n$ gerad- oder verzweigtkettige Reste im Falle von $(CH_2)_m$ mit 0 bis 5 Kohlenstoffatomen in der Hauptkette, und im Falle von $(CH_2)_n$ mit 1 bis 4 Kohlenstoffatomen in der Hauptkette einschließen und einen oder mehrere Niederalkyl- oder Halogenresten enthalten können;

55

zur Herstellung eines Arzneimittels zur Behandlung von Allergien.

2. Verwendung nach Anspruch 1, wobei R^1 einen Alkylrest, eine Phenylgruppe oder einen Phenylalkylrest

bedeutet.

3. Verwendung nach Anspruch 1, wobei R¹ eine Phenylgruppe oder einen Phenylalkylrest, R² ein Wasserstoffatom und R³ eine Phenylgruppe, eine Biphenylgruppe oder einen Cycloalkylrest bedeutet und m 1 oder 2 oder 3 ist.

5 4. Verwendung nach Anspruch 1, wobei die Verbindung N-Hydroxy-N-methyl[1,1'-biphenylyl]-4-acetamid ist.

10 5. Verwendung nach Anspruch 1, wobei die Verbindung N-(1,1'-Dimethylethyl)-N-hydroxy[1,1'-biphenylyl]-4-acetamid ist.

6. Verwendung nach Anspruch 1, wobei die Verbindung N-Hydroxy-N-phenylbenzolbutanamid ist.


15 7. Verwendung nach Anspruch 1, wobei die Verbindung N-Hydroxy-N-(phenylmethyl)cyclohexanacetamid ist.

8. Verwendung nach Anspruch 1, wobei die Verbindung N-Hydroxy-N-(phenylmethyl)benzolbutanamid ist.

20 9. Verwendung nach Anspruch 1, wobei die Verbindung N-Hydroxy-N-pentylbenzolbutanamid ist.

10. Verbindung mit der Struktur


25



30

in der R¹ ein Wasserstoffatom, einen Niederalkyl-, Aryl-, Niederalkenyl-, Cycloalkyl- oder Aralkylrest oder die Gruppe

35



40

bedeutet, in der n 1 bis 4 beträgt, und X eine Hydroxygruppe, einen Alkoxyrest, eine Aminogrupp , einen C₁-C₄-Alkylamino- oder C₁-C₄-Dialkylaminorest bedeutet,

R² einen Niederalkylrest darstellt;

R³ einen C₁-C₂₀-Alkyl-, C₃-C₂₀-Alkenyl-, Aryl-, Arylalkyl-, Cycloalkyl-, Arylalkenyl-, Niederalkoxy-, Niederalkenyoxy-, Arylalkoxy- oder Cycloalkyloxyrest darstellt; und

m 1 bis 5 beträgt;

45

oder eine solche Verbindung in Form eines pharmazeutisch verträglichen einbasigen oder zweibasigen Salzes, wobei die Begriffe "Niederalkyl", "Alkyl", "Cycloalkyl", "Aryl", "Alkenyl", "(CH₂)_m" und "(CH₂)_n" die Bedeutungen gemäß Anspruch 1 haben.

50

11. Verbindung nach Anspruch 10, in der R¹ einen Alkylrest, eine Phenylgruppe oder ein Phenylalkylrest bedeutet.

12. N-Hydroxy-N-methyl[1,1'-biphenylyl]-4-acetamid.

13. N-(1,1'-Dimethylethyl)-N-hydroxy[1,1'-biphenylyl]-4-acetamid.

55 14. N-Hydroxy-N-phenylbenzolbutanamid.

15. N-Hydroxy-N-(phenylmethyl)cyclohexanacetamid.

16. N-Hydroxy-N-(phenylmethyl)benzolbutanamid.

17. N-Hydroxy-N-pentylbenz Ibutanamid.

5

10

15

20

25

30

35

40

45

50

55